Story
Bernstein Sees 33% Downside for Novo Nordisk, Cuts Forecasts on Eli Lilly Threat

Bernstein has significantly lowered its long-term earnings forecasts for Novo Nordisk A/S (NOVOb), citing intensifying competition from rival Eli Lilly (LLY) in the U.S. market for GLP-1 drugs. The investment firm maintained its "Underperform" rating on the stock, projecting a potential 33% downside from its August 7 closing price.
Forecasts Slashed on Competitive Pressures
Analysts at the firm cut their adjusted earnings-per-share (EPS) estimates for the 2026-2031 period, placing them well below market consensus. The move was driven by expectations that Novo Nordisk will lose more market share than previously anticipated to Eli Lilly's injectable obesity and diabetes treatments in the United States.
Key forecast reductions include:
- 2026 EPS Estimate: Lowered to 20.19 Danish kroner, which is 7% below the Bloomberg consensus of 21.74 kroner.
- 2031 EPS Estimate: Cut to 24.20 Danish kroner, representing a 15% gap below the consensus of 28.31 kroner.
Bernstein also anticipates that Novo's forthcoming Wegovy Pill will lose majority share in the U.S. oral obesity market to Lilly’s competing drug, Foundayo, by 2028. The firm warned of worsening U.S. price deflation for GLP-1 drugs, which could lead to margin misses.
AdValuation and Pipeline Concerns
Despite raising its price target slightly to 203 Danish kroner from 200 kroner, Bernstein's valuation implies significant risk. The new target is 33% below the stock's 305.10 kroner close on August 7. The firm noted its bull/bear scenario analysis remains "negatively skewed," with a potential 4% upside versus a 40% downside to its 2035 operating profit estimates.
Analysts stated that "the catalyst cupboard looks bare" for Novo Nordisk. They highlighted that Cagri-sema, a key pipeline drug, is no longer viewed as a source of upside risk after its REDEFINE-4 trial failed to show non-inferiority to Lilly’s Zepbound in a February 2026 readout. The minor price target increase was attributed to new, below-consensus sales projections for coramitug, an antibody for a rare heart disease.
Market Pricing in 'Extreme' Growth
Bernstein's valuation is based on a discounted cash flow (DCF) model and an EV/EBITA multiples analysis, both of which apply a 30% discount to European pharmaceutical peers. The firm argued that the current share price implies a perpetuity growth rate of 5%, which it called "extreme" given the looming patent expiries for its key drug, semaglutide, between 2026 and 2032.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.